Effect of naringenin on the pharmacokinetics of metoprolol succinate in rats
The aim of the present study was to investigate the effect of naringenin (4,5,7-trihydroxy flavonone) on the pharmacokinetics of metoprolol, a substrate of Cytochrome P-450 3A4 (CYP3A4), CYP2C9, and CYP2D6 in rats.Male Wistar rats were treated orally with metoprolol (30 mg/kg) alone and in combination with naringenin (25, 50, and 100 mg/kg) once daily for 15 consecutive days.The plasma concentrations of metoprolol were determined using Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) on the 1st day in single-dose pharmacokinetic (PK) study (SDS) and on the 15th day in multiple dosing PK studies (MDS).Compared to the metoprolol control group, the Cmax, AUC, and half-life (T1/2) of metoprolol increased in rats pre-treated with naringenin, while there was no significant change in Tmax. There is a significant decrease in clearance and volume of distribution.The present study results revealed that naringenin significantly enhanced the Cmax, AUC, MRT, t1/2, and decreased the clearance of metoprolol possibly through the inhibition of CYP enzymes involved in the metabolism of metoprolol.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Xenobiotica; the fate of foreign compounds in biological systems - 51(2021), 8 vom: 14. Aug., Seite 926-932 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pingili, Ravindra Babu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bioavailability |
|---|
| Anmerkungen: |
Date Completed 23.07.2021 Date Revised 23.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/00498254.2021.1942311 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326862366 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326862366 | ||
| 003 | DE-627 | ||
| 005 | 20231225195518.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/00498254.2021.1942311 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1089.xml |
| 035 | |a (DE-627)NLM326862366 | ||
| 035 | |a (NLM)34138683 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pingili, Ravindra Babu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of naringenin on the pharmacokinetics of metoprolol succinate in rats |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.07.2021 | ||
| 500 | |a Date Revised 23.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The aim of the present study was to investigate the effect of naringenin (4,5,7-trihydroxy flavonone) on the pharmacokinetics of metoprolol, a substrate of Cytochrome P-450 3A4 (CYP3A4), CYP2C9, and CYP2D6 in rats.Male Wistar rats were treated orally with metoprolol (30 mg/kg) alone and in combination with naringenin (25, 50, and 100 mg/kg) once daily for 15 consecutive days.The plasma concentrations of metoprolol were determined using Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) on the 1st day in single-dose pharmacokinetic (PK) study (SDS) and on the 15th day in multiple dosing PK studies (MDS).Compared to the metoprolol control group, the Cmax, AUC, and half-life (T1/2) of metoprolol increased in rats pre-treated with naringenin, while there was no significant change in Tmax. There is a significant decrease in clearance and volume of distribution.The present study results revealed that naringenin significantly enhanced the Cmax, AUC, MRT, t1/2, and decreased the clearance of metoprolol possibly through the inhibition of CYP enzymes involved in the metabolism of metoprolol | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CYP2C9 | |
| 650 | 4 | |a CYP2D6 | |
| 650 | 4 | |a CYP3A4 | |
| 650 | 4 | |a Metoprolol | |
| 650 | 4 | |a Naringenin | |
| 650 | 4 | |a bioavailability | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 7 | |a Cytochrome P-450 CYP2D6 Inhibitors |2 NLM | |
| 650 | 7 | |a Flavanones |2 NLM | |
| 650 | 7 | |a Metoprolol |2 NLM | |
| 650 | 7 | |a GEB06NHM23 |2 NLM | |
| 650 | 7 | |a naringenin |2 NLM | |
| 650 | 7 | |a HN5425SBF2 |2 NLM | |
| 700 | 1 | |a Vemulapalli, Sridhar |e verfasserin |4 aut | |
| 700 | 1 | |a Dirisala, Vijaya R |e verfasserin |4 aut | |
| 700 | 1 | |a Mullapudi, Surya Sandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Gullapalli, Yamini |e verfasserin |4 aut | |
| 700 | 1 | |a Kilaru, Naveen Babu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Xenobiotica; the fate of foreign compounds in biological systems |d 1971 |g 51(2021), 8 vom: 14. Aug., Seite 926-932 |w (DE-627)NLM000064742 |x 1366-5928 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2021 |g number:8 |g day:14 |g month:08 |g pages:926-932 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/00498254.2021.1942311 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2021 |e 8 |b 14 |c 08 |h 926-932 | ||